Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.20.2
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2020
USD ($)
Sep. 30, 2015
item
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2019
USD ($)
Licensing and other arrangements                  
Revenue from contracts with customers     $ 200 $ 8,525 $ 753 $ 17,176      
Novartis International | License Agreement                  
Licensing and other arrangements                  
Agreement termination prior written notice period   180 days              
Number of performance obligations | item   1              
Revenue from contracts with customers     0 $ 0 0 $ 0 $ 10,000 $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones         470,000        
Royalty payment period   10 years              
Contract assets     0   0       $ 0
Contract liabilities     0   0       0
Capitalized contract costs     $ 0   $ 0       $ 0
Novartis International | License Agreement | Subsequent Event                  
Licensing and other arrangements                  
Revenue from contracts with customers $ 25,000